ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
0,00%
Bitcoin
66.094,87
-0,15%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) News

NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NKTR
DatumZeitQuelleÜberschriftSymbolFirma
15/06/202400h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
14/06/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
12/06/202415h30PR Newswire (US)Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024NASDAQ:NKTRNektar Therapeutics
06/06/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
06/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NKTRNektar Therapeutics
05/06/202423h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NKTRNektar Therapeutics
31/05/202400h00PR Newswire (US)Nektar Management to Present at Upcoming Investor ConferencesNASDAQ:NKTRNektar Therapeutics
28/05/202422h51Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NKTRNektar Therapeutics
21/05/202403h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/05/202403h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
21/05/202403h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
17/05/202422h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
17/05/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
17/05/202422h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
13/05/202422h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
09/05/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
09/05/202422h15PR Newswire (US)Nektar Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
03/05/202400h00PR Newswire (US)Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
22/03/202419h00PR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
05/03/202423h11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NKTRNektar Therapeutics
05/03/202415h00PR Newswire (US)Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataNASDAQ:NKTRNektar Therapeutics
04/03/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
04/03/202422h15PR Newswire (US)Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
04/03/202414h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
04/03/202414h30PR Newswire (US)Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNASDAQ:NKTRNektar Therapeutics
28/02/202400h00PR Newswire (US)Nektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:NKTRNektar Therapeutics
27/02/202400h00PR Newswire (US)Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
23/02/202402h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
23/02/202402h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
23/02/202402h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
 Showing the most relevant articles for your search:NASDAQ:NKTR

Kürzlich von Ihnen besucht

LSE
US19
Macquarie 32
COIN
OGNUSD
OriginToken
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten